ESTRO 2024 - Abstract Book

S1373

Clinical - Head & neck

ESTRO 2024

Our hypothesis that patients with p16-negative HNSCC report inferior pre-radiotherapy HR-QoL was confirmed. Such patients are also more likely to experience severe problems in performing their usual activities, even when adjusting for clinical variables. This work highlights the usefulness of routinely-collected ePROM data in detecting differences in HR-QoL for patients with HNSCC and the need for adequate support to improve HR-QoL for patients with p16-negative HNSCC.

Keywords: HPV, quality of life, patient reported outcomes

2039

Poster Discussion

Validation and Utility of Circulating Tumor Tissue Modified Viral HPV DNA in a Community HN-MDC

Olga Russial, Adam Raben, Sophia Shah, Sujong Park, Lydia Clements, Neil Hockstein, Jennifer Cormier, Tim Kegelman

Helen F. Graham Cancer Center, Radiation Oncology, Newark, USA

Purpose/Objective:

HPV driven OPSCC incidence is rising in many smaller community-based cancer programs in the USA. At the same time, the emergence of biomarkers for diagnosis and then monitor tumor recurrence is exciting but require prospective validation. Circulating tumor tissue modified viral (TTMV)-HPV DNA released into the bloodstream is an emerging tool to aid in the diagnosis and surveillance of patients with HPV+OPSCC. Our site was chosen as one of the early prospective adopters of the use of TTMV-HPV DNA in a community-based HN MDC for patients at time of diagnosis to confirm HPV and for post treatment surveillance. Analysis of our experience was undertaken to validate the sensitivity of this molecular HPV marker for broader clinical utility.

Material/Methods:

Between 2020- 2023, A total of 401 TTMV-HPV DNA assays (NavDx®, Naveris Laboratories) were prospectively collected on 115 pts diagnosed with OPSCC and treated in a community hospital based HN-MDC. Initial HPV status was assessed by either tissue biopsy or FNA by p16 marker and then by blood drawn TTMV-HPV DNA assay to confirm HPV16, or 18,33, or 35, and correlated with imaging and clinical exam. All pts were treated with curative intent. Post treatment TTMV testing was generally done at 3 month intervals from the completion of treatment along with clinical follow-up and diagnostic studies as per NCCN guidelines to monitor for recurrence. Inclusion criteria for this analysis included +Nav DX, completion of curative treatment and at least one TTMV > 3 month post treatment test. Surveillance tests were primarily collected every three months after treatment completion for the first two years and every six months thereafter.

Results: